(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
07 September 2023 (07.09.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/166418 A3

(51) International Patent Classification:
C07K 16/24 (2006.01)

(21) International Application Number:
PCT/IB2023/051858

(22) International Filing Date:
28 February 2023 (28.02.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/268,817 03 March 2022 (03.03.2022) US
63/483,162 03 February 2023 (03.02.2023) US

(71) Applicant: **PFIZER INC.** [US/US]; 66 Hudson Boulevard East, New York, New York 10001-2192 (US).

(72) Inventors: **AGOSTINELLI, Rita Diane**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **APGAR, James Reasoner**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **BARRON, Alexander Michael Shuford**; c/o Pfizer Inc., 1 Portland Street, Cambridge, Massachusetts 02139 (US). **BENNETT, Eric Matthew**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **BLOOM, Laird**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **CHEN, Ting**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **D'ANTONA, Aaron Michael**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **DE, Arnab**; c/o Pfizer Inc., 1 Burtt Rd, A200, Andover, Massachusetts 01810 (US). **GIESECK III, Richard Lee**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **JIN, Fang**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **KASAIAN, Marion Teresa**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **LAMBERT, Matthew Allister**; c/o Pfizer Ireland Pharmaceuticals, Grange Castle Business Park, Clondalkin, Dublin, 22 (IE). **MARQUETTE, Kimberly Ann**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **MCMANUS, Virginie**; c/o Pfizer Ireland Pharmaceuticals, Grange Castle Business Park, Clondalkin, Dublin, 22 (IE). **MIN DEBARTOLO, Jessica Haewon**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **PICHE-NICHOLAS, Nicole Melissa**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **SHELDON, Richard Thomas**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **TCHISTIAKOVA, Lioudmila**; 3 O'Grady Circle, Stoneham, Massachusetts 02180 (US). **ZHONG, Xiaotian**; c/

(54) Title: MULTISPECIFIC ANTIBODIES BINDING TO IL-4, IL-13 AND/OR TSLP AND USES THEREOF



FIG.37

(57) Abstract: The present disclosure relates to antibodies that specifically bind to one or more of IL-4, IL-13, IL-33, TSLP, and p40. The present disclosure further relates to antibodies that bind to one of IL-4, IL-13, IL-33, or TSLP. The disclosure further relates to multispecific antibodies that specifically bind to IL-4 and IL-13, and at least one other target. The present disclosure relates to multispecific antibodies that bind IL-4, IL-13, and one of IL-33, TSLP, or p40. The present disclosure also pertains to related molecules, e.g. nucleic acids which encode such antibodies or multispecific antibodies, compositions, and related methods, e.g., methods for producing and purifying such antibodies and multispecific antibodies, and their use in diagnostics and therapeutics.

WO 2023/166418 A3

[Continued on next page]

o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US).

(74) **Agent: ZIELINSKI, Bryan C.**; PFIZER INC., 100 Route 206 North, Mail Stop: SOM-PPK4-LLA-403, Peapack, New Jersey 07977 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(88) **Date of publication of the international search report:**
12 October 2023 (12.10.2023)